Şunu aradınız:: alendronat (Hırvatça - İngilizce)

alendronat
alendronate

Što je alendronat?
what is alendronate?

alendronat se ne smije primjenjivati tijekom dojenja.
alendronate should not be used during breast-feeding.

alendronat može nadražiti sluznicu gornjeg dijela gastrointestinalnog trakta.
alendronate can cause local irritation of the upper gastrointestinal mucosa.

nema dokaza da se alendronat metabolizira u životinja niti u ljudi.
there is no evidence that alendronate is metabolised in animals or humans.

nije poznato izlučuju li se alendronat/metaboliti u majčino mlijeko.
it is unknown whether alendronate/metabolites are excreted in human milk.

nije poznato izlučuju li se alendronat/metaboliti u majčino mlijeko u ljudi.
it is unknown whether alendronate/metabolites are excreted in human milk.

natrijev alendronat je ispitivan u malobrojnih bolesnika mlađih od 18 godina s osteogenesis imperfecta.
alendronate sodium has been studied in a small number of patients with osteogenesis imperfecta under the age of 18 years.

bioraspoloživost je bila zanemariva kad se alendronat uzimao sa standardiziranim doručkom ili do dva sata nakon njega.
bioavailability was negligible whether alendronate was administered with, or up to two hours after, a standardised breakfast.

dođe li do predoziranja adrovance tabletama, bolesnici se moraju dati mlijeko ili antacidi kako bi vezali alendronat.
in case of overdose with adrovance, milk or antacids should be given to bind alendronate.

natrijev alendronat je bisfosfonat koji inhibira resorpciju kosti posredovanu osteoklastima, bez izravnog utjecaja na formiranje kosti.
alendronate sodium is a bisphosphonate that inhibits osteoclastic bone resorption with no direct effect on bone formation.

u ispitivanjima liječenja osteoporoze alendronat je bio učinkovit kada se primjenjivao najmanje 30 minuta prije uzimanja prvog dnevnog obroka ili napitka.
in osteoporosis studies, alendronate was effective when administered at least 30 minutes before the first food or beverage of the day.

u skotnih ženki štakora alendronat je uzrokovao otežan okot povezan s hipokalcijemijom (vidjeti dio 5.3).
alendronate given during pregnancy in rats caused dystocia related to hypocalcaemia (see section 5.3).

fosavance je kombinirana tableta koja sadrži dvije djelatne tvari, natrijev alendronat trihidrat i kolekalciferol (vitamin d3).
fosavance is a combination tablet containing the two active substances alendronate sodium trihydrate and colecalciferol (vitamin d3).

ako ste alergični na natrijev alendronat trihidrat, kolekalciferol ili neki drugi sastojak ovog lijeka (naveden u dijelu 6.),
if you are allergic to alendronate sodium trihydrate, colecalciferol or any of the other ingredients of this medicine (listed in section 6),

alendronat se u štakora ne eliminira kiselinskim ni baznim transportnim sustavom bubrega, pa se stoga ne očekuje da bi alendronat u čovjeka interferirao s eliminacijom drugih lijekova koji se eliminiraju putem tog sustava.
alendronate is not excreted through the acidic or basic transport systems of the kidney in rats, and thus it is not anticipated to interfere with the excretion of other medicinal products by those systems in humans.

adrovance je tableta koja sadrži dvije djelatne tvari, alendronatnu kiselinu (koja se često naziva alendronat) i kolekalciferol, poznat kao vitamin d3.
adrovance is a tablet containing the two active substances, alendronic acid (commonly called alendronate) and colecalciferol known as vitamin d3.

fit ispitivanje sastojalo se od dva placebom kontrolirana ispitivanja u kojima je alendronat primjenjivan kao dnevna terapija (5 mg na dan u trajanju od dvije godine i 10 mg na dan u trajanju od još jedne ili dvije dodatne godine):
fit consisted of two placebo-controlled studies using alendronate daily (5 mg daily for two years and 10 mg daily for either one or two additional years):

temeljem podataka iz ispitivanja o prijelazu s jedne terapije na drugu (alendronat u denosumab) u postmenopauzalnih žena s osteoporozom, farmakokinetika i farmakodinamika denosumaba nije se mijenjala zbog ranije terapije alendronatom.
in postmenopausal women with osteoporosis the pharmacokinetics and pharmacodynamics of denosumab were not altered by previous alendronate therapy, based on data from a transition study (alendronate to denosumab).

ako uzimate bilo koji drugi lijek za koji je poznato da na njega utječe željezo (kao što su lijekovi koji sadrže djelatnu tvar alendronat ili doksiciklin), svakako uzmite taj lijek najmanje jedan sat prije ili dva sata poslije uzimanja lijeka velphoro.
if you are taking any other medicine that is known to be affected by iron (for example medicines containing the active substance alendronate or doxycycline), make sure that you take this medicine at least one hour before taking velphoro or at least two hours after taking velphoro.